Welcome to LookChem.com Sign In|Join Free

CAS

  • or

123664-52-8

Post Buying Request

123664-52-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

123664-52-8 Usage

General Description

Iguratimod Impurity 3 is a chemical compound that is classified as an impurity of the drug Iguratimod. It is a potential impurity that may be present in the Iguratimod drug substance, and it is important to monitor and control its levels during the drug manufacturing process. Iguratimod Impurity 3 is a product of the degradation or transformation of the Iguratimod molecule, and its presence in the drug substance can impact the safety, efficacy, and quality of the final drug product. Therefore, it is essential for pharmaceutical companies to conduct thorough analysis and testing to ensure that Iguratimod Impurity 3 levels are within acceptable limits in the Iguratimod drug substance.

Check Digit Verification of cas no

The CAS Registry Mumber 123664-52-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,3,6,6 and 4 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 123664-52:
(8*1)+(7*2)+(6*3)+(5*6)+(4*6)+(3*4)+(2*5)+(1*2)=118
118 % 10 = 8
So 123664-52-8 is a valid CAS Registry Number.

123664-52-8Relevant articles and documents

Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6- phenoxychromones. Antiarthritic effect of the 3-formylamino compound (T-614) in chronic inflammatory disease models

Inaba, Takihiro,Tanaka, Keiichi,Takeno, Ryuko,Nagaki, Hideyoshi,Yoshida, Chosaku,Takano, Shuntaro

, p. 131 - 139 (2007/10/03)

A group of derivatives of 7-methanesulfonylamino-6-phenoxychromone (1) at the pyrone and phenoxy rings was synthesized starting with 4-chloro-3- nitroanisole and evaluated against acute and chronic inflammations in oral administration in animals. Significant potency in the rat models of carrageenin-induced edema (CPE) and adjuvant-induced arthritis (AA) was realized with 2'-fluoro and 2',4'-difluoro derivatives (9a and 9d), and 3- formylamino derivative (19a) and its 2'-fluoro and 2',4'-difluoro compounds (22a and 22d), displaying AA therapeutic effect of ED40=2.5-7.1 mg/kg/d for 7 d and AA prophylactic effect of 53-70% inhibition at the dosage of 3 mg/kg/d for 22 d. To identify a candidate for further pharmacological study, the five compounds were subjected to evaluation of their gastro-ulcerogenic liability, leading to selection of the fluorine-free compound 19a which did not cause acute ulceration at 300 mg/kg in oral administration in rats. Compound 19a (ED40=3.6 mg/kg in established AA) possessed good therapeutic efficacy against type II collagen-induced arthritis in DBA/1J mice with doses of 30 and 100 mg/kg, suggesting the development of 19a (designated T-614) as a prospective disease-modifying antirheumatic agent. In addition, a preparative-scale synthetic route to T-614 has been established.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 123664-52-8